LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Strona główna・Stock List・Biogen Inc

Biogen Inc

Closed

SectorHealthcare

140.29 0.24

Buy Sell

Overview

Share price change

24h

Current

Min

140.04

Max

141.94

Key metrics
By Trading Economics
Income	394M 635M
Sales	215M 2.6B
P/E Sector Avg	12.653 35.733
EPS	3.02
Profit margin	23.995
Employees	7,605
EBITDA	457M 1B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+20.72% upside

Dividends
By Dow Jones
Next Earnings	29 paź 2025

Market Stats
By TradingEconomics
Market Cap	442M 19B
Previous open	140.05
Previous close	140.29

News Sentiment

By Acuity

31%

69%

92 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

118.15 / 121.17 Support & Resistance

Biogen Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 wrz 2025, 09:30 UTC

Acquisitions, Mergers, Takeovers

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 wrz 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 wrz 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 wrz 2025, 20:37 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 wrz 2025, 20:37 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 wrz 2025, 20:36 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 wrz 2025, 20:36 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 wrz 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 wrz 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 wrz 2025, 20:31 UTC

Acquisitions, Mergers, Takeovers

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 wrz 2025, 20:20 UTC

Earnings

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 wrz 2025, 19:23 UTC

Market Talk

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 wrz 2025, 19:22 UTC

Earnings

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 wrz 2025, 19:17 UTC

Market Talk

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 wrz 2025, 18:59 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 wrz 2025, 18:35 UTC

Market Talk

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 wrz 2025, 17:25 UTC

Market Talk

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 wrz 2025, 17:20 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 wrz 2025, 17:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 wrz 2025, 17:17 UTC

Market Talk

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 wrz 2025, 17:03 UTC

Market Talk

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 wrz 2025, 16:39 UTC

Acquisitions, Mergers, Takeovers

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 wrz 2025, 16:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

5 wrz 2025, 16:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

5 wrz 2025, 16:37 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 wrz 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 wrz 2025, 16:16 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

20.72% upside

12 Months Forecast

Average 169.81 USD 20.72%

High 260 USD

Low 118 USD

Based on 26 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

26 ratings

Buy

Hold

Sell

Based on 26 analysts giving stock ratings to Biogen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

118.15 / 121.17Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

92 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.